Acquisition by Cittadine Andrew of 25000 shares of Monopar Therapeutics at 0.6146 subject to Rule 16b-3
| MNPR Stock | USD 41.46 2.14 5.44% |
Slightly above 56% of all Monopar Therapeutics' retail investors are looking to take a long position. The analysis of the overall investor sentiment regarding Monopar Therapeutics suggests that some traders are interested. Monopar Therapeutics' investing sentiment overview a quick insight into current market opportunities from investing in Monopar Therapeutics. Many technical investors use Monopar Therapeutics stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Monopar |
Filed transaction by Monopar Therapeutics Officer: Chief Operating Officer. Grant, award or other acquisition pursuant to Rule 16b-3(d)
Read at macroaxis.com
Monopar Therapeutics Fundamental Analysis
We analyze Monopar Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Monopar Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Monopar Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Current Asset
Current Asset Comparative Analysis
Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.
Monopar Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Monopar Therapeutics stock to make a market-neutral strategy. Peer analysis of Monopar Therapeutics could also be used in its relative valuation, which is a method of valuing Monopar Therapeutics by comparing valuation metrics with similar companies.
Peers
Monopar Therapeutics Related Equities
| ADAG | Adagene | 5.00 | ||||
| ACXP | Acurx Pharmaceuticals | 4.82 | ||||
| RZLT | Rezolute | 3.74 | ||||
| AVTE | Aerovate Therapeutics | 1.17 | ||||
| DMAC | DiaMedica Therapeutics | 0.80 | ||||
| MOLN | Molecular Partners | 0.57 | ||||
| SCPH | Scpharmaceuticals | 0.30 | ||||
| PEPG | PepGen | 0.51 | ||||
| ANTX | AN2 Therapeutics | 0.79 | ||||
| PMVP | Pmv Pharmaceuticals | 1.44 | ||||
| KTTA | Pasithea Therapeutics | 2.01 | ||||
| CADL | Candel Therapeutics | 2.41 | ||||
| ANEB | Anebulo Pharmaceuticals | 2.53 | ||||
| MLYS | Mineralys Therapeutics, | 2.83 | ||||
| PHVS | Pharvaris | 3.00 | ||||
| ACRV | Acrivon Therapeutics, | 4.22 |
Additional Tools for Monopar Stock Analysis
When running Monopar Therapeutics' price analysis, check to measure Monopar Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Monopar Therapeutics is operating at the current time. Most of Monopar Therapeutics' value examination focuses on studying past and present price action to predict the probability of Monopar Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Monopar Therapeutics' price. Additionally, you may evaluate how the addition of Monopar Therapeutics to your portfolios can decrease your overall portfolio volatility.